Differences in <scp>PD</scp>‐<scp>L1</scp>, <scp>PD</scp>‐<scp>L2</scp>, and <scp>EGFR</scp> Expression Between Naive and Recurrent Tumors in Patients With Head and Neck Squamous Cell Carcinoma: A Retrospective Study
The expression of immune checkpoints including PD-L1 in naive tumors does not reflect those in recurrent tumors. Increasing PD-L1 expression in immune cells may cause early recurrence of HNSCC.
Authors
- Risa Wakisaka
- Hiroki Komatsuda (ORCID: https://orcid.org/0000-0002-3783-2746)
- Miki Takahara (ORCID: https://orcid.org/0000-0003-0535-5778)
- Toshihiro Nagato (ORCID: https://orcid.org/0000-0001-8326-8296)
- Takahiro Inoue (ORCID: https://orcid.org/0000-0002-7710-1526)
- Michihisa Kono (ORCID: https://orcid.org/0000-0002-8506-928X)
- Ryosuke Sato (ORCID: https://orcid.org/0000-0001-5899-3410)
- Takumi Kumai
- Akemi Kosaka (ORCID: https://orcid.org/0000-0001-5599-3685)
- Kan Kishibe (ORCID: https://orcid.org/0000-0003-4830-2051)
- Takayuki Ohkuri (ORCID: https://orcid.org/0000-0002-6889-7809)
- Hidekiyo Yamaki
- Hiroya Kobayashi (ORCID: https://orcid.org/0000-0001-5222-8961)
- Kenzo Ohara (ORCID: https://orcid.org/0000-0002-6957-6206)
Institutions
- Asahikawa Medical University (JP)
Publication Details
- Journal
- Head & Neck
- Published
- 2025-03-28
- DOI
- https://doi.org/10.1002/hed.28151
- Citations
- 3
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 3.14